| Biomarker ID | 556 |
| PMID | 20977276 |
| Year | 2011 |
| Biomarker | Lamin A; Cytokeratin-1; Mimecan; Prostatic acid phosphatase; Prostate-specific antigen; |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Downregulated (with Regulation Coefficient): Lamin A [-1.52]; Cytokeratin-1 [-1.09]; Mimecan [-1.08]; Prostatic acid phosphatase [-2.85]; Prostate-specific antigen [-1.15]; |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include(ACP3):-Immune System, Innate Immune System, ATP/ITP metabolism,Neutrophil degranulation Pathways Iclude (KLK3):-ID regulation of gene expression,Prostate cancer, Androgen receptor proteolysis and transcription regulation, Androgen receptor signaling, proteolysis, and transcription regulation, Insulin-like growth factor (IGF) activity regulation by insulin-like growth factor binding proteins (IGFBPs) |
| Experiment | Gleason 6 Vs Benign Prostate |
| Type of Biomarker | Diagnostic |
| Cohort | 46 patients were chosen for the study such that 23 had a gleason score of 6 and 23 had a score of 8 or higher. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | Two-Dimensional Differential in Gel Electrophoresis (2-D DIGE) |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | LMNA, KRT, OGN, ACP3, KLK3 |